Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.30 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.30 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26929264 | 1.00 | TSHR (0.33) | TSHRHSD11B1ALDH1A1PDK1PDK2 | |
| SCHEMBL11287206 | 0.74 | — | — | |
| SCHEMBL3814475 | 0.74 | TSHR (0.40) | TSHRALDH1A1 | |
| SCHEMBL10895888 | 0.74 | — | — | |
| SCHEMBL2020575 | 0.74 | — | — | |
| SCHEMBL2373075 | 0.71 | CPA1 (0.33) | — | |
| SCHEMBL1700917 | 0.70 | LMNA (0.33) | TSHRALDH1A1 | |
| SCHEMBL27464807 | 0.70 | — | — | |
| SCHEMBL9481025 | 0.70 | — | — | |
| SCHEMBL5907560 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361500-A1 | (S)-ENGINEERED OXYNITRILASE POLYPEPTIDES AND USES THEREOF | NOVARTIS AG (CH) | 2025-11-27 | — | — | US | claimed |
| EP-4536822-A1 | (S)-ENGINEERED OXYNITRILASE POLYPEPTIDES AND USES THEREOF | Novartis AG (CH) | 2025-04-16 | — | — | EP | claimed |
| WO-2023238078-A1 | (S)-ENGINEERED OXYNITRILASE POLYPEPTIDES AND USES THEREOF | NOVARTIS AG (CH) | 2023-12-14 | — | — | WO | claimed |
| US-20250361500-A1 | (S)-ENGINEERED OXYNITRILASE POLYPEPTIDES AND USES THEREOF | NOVARTIS AG (CH) | 2025-11-27 | — | — | US | disclosed |
| EP-4536822-A1 | (S)-ENGINEERED OXYNITRILASE POLYPEPTIDES AND USES THEREOF | Novartis AG (CH) | 2025-04-16 | — | — | EP | disclosed |
| US-11911371-B2 | Pyridine and pyrazine derivative for the treatment of chronic bronchitis | NOVARTIS AG (CH) | 2024-02-27 | — | — | US | disclosed |
| US-20240058315-A1 | Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis | NOVARTIS AG (CH) | 2024-02-22 | — | — | US | disclosed |
| WO-2023238078-A1 | (S)-ENGINEERED OXYNITRILASE POLYPEPTIDES AND USES THEREOF | NOVARTIS AG (CH) | 2023-12-14 | — | — | WO | disclosed |
| CN-113527191-B | Preparation method of 2,3-dichloro-5-trifluoromethylpyridine | 新发药业有限公司 | 2023-04-07 | — | — | CN | disclosed |
| EP-3980121-A1 | PYRIDINE AND PYRAZINE DERIVATIVE FOR THE TREATMENT OF CF, COPD, AND BRONCHIECTASIS | Novartis AG (CH) | 2022-04-13 | — | — | EP | disclosed |
| CN-113891744-A | Pyridine and pyrazine derivatives for the treatment of CF, COPD and bronchiectasis | 诺华股份有限公司 | 2022-01-04 | — | — | CN | disclosed |
| US-20150045364-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | NOVARTIS AG (CH) | 2015-02-12 | — | — | US | disclosed |
| US-20140135329-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | BAETTIG URS (GB) | 2014-05-15 | — | — | US | disclosed |
| US-8476269-B2 | Pyridine and pyrazine derivative for the treatment of CF | NOVARTIS AG (CH) | 2013-07-02 | — | — | US | disclosed |
| WO-2013038381-A1 | PYRIDINE/PYRAZINE AMIDE DERIVATIVES | NOVARTIS AG (CH) | 2013-03-21 | — | — | WO | disclosed |
| EP-2547656-A1 | PYRIDINE AND PYRAZINE DERIVATIVE FOR THE TREATMENT OF CF | Novartis AG (CH) | 2013-01-23 | — | — | EP | disclosed |
| US-20120277232-A1 | Pyridine and Pyrazine Derivative for the Treatment of CF | NOVARTIS AG | 2012-11-01 | — | — | US | disclosed |
| US-8247436-B2 | Pyridine and pyrazine derivative for the treatment of CF | NOVARTIS AG (CH) | 2012-08-21 | — | — | US | disclosed |
| US-20110230483-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | NOVARTIS AG | 2011-09-22 | — | — | US | disclosed |
| WO-2011113894-A1 | PYRIDINE AND PYRAZINE DERIVATIVE FOR THE TREATMENT OF CF | NOVARTIS AG (CH) | 2011-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230483-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | CFTR, OPRK1, OPRD1 | TSHR 2129/4885HSD11B1 3223/4885ALDH1A1 2710/4885 |
| US-11911371-B2 | Pyridine and pyrazine derivative for the treatment of chronic bronchitis | CFTR, OPRK1, CHRM3 | TSHR 2138/4885HSD11B1 3087/4885ALDH1A1 2546/4885 |
| US-20240058315-A1 | Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis | CFTR, OPRK1, CHRM3 | TSHR 1762/4885HSD11B1 2921/4885ALDH1A1 2914/4885 |
| US-20120277232-A1 | Pyridine and Pyrazine Derivative for the Treatment of CF | CFTR, OPRK1, OPRD1 | TSHR 2129/4885HSD11B1 3223/4885ALDH1A1 2710/4885 |
| US-20150045364-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | CFTR, OPRK1, OPRD1 | TSHR 2129/4885HSD11B1 3223/4885ALDH1A1 2710/4885 |
| US-20140135329-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | CFTR, OPRK1, OPRD1 | TSHR 2129/4885HSD11B1 3223/4885ALDH1A1 2710/4885 |
| US-20250361500-A1 | (S)-ENGINEERED OXYNITRILASE POLYPEPTIDES AND USES THEREOF | ADH5, ADH1C, ADH1A | TSHR 3605/4885HSD11B1 220/4885ALDH1A1 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.